Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 24, Pages -Publisher
MDPI
DOI: 10.3390/jcm10245845
Keywords
chronic lymphocytic leukemia; ibrutinib; Richter transformation
Categories
Ask authors/readers for more resources
Ibrutinib has shown significant clinical impact in treating patients with chronic lymphocytic leukemia, including those with unfavorable cytogenetics and molecular markers. The drug is effective and well tolerated, with durable responses and a favorable safety profile in real-life settings. Adverse reactions mainly include hematological and extrahematological toxicities.
Ibrutinib has demonstrated a significant clinical impact in patients with de novo and relapsed/refractory chronic lymphocytic leukemia (CLL), even in cases with unfavorable cytogenetics and molecular markers. All CLL patients' data treated at our Institute with ibrutinib have been retrospectively reviewed. Forty-six patients received ibrutinib either as frontline (10) or second or more advanced treatment (36). Five patients presented with TP53 mutations; 11 had the deletion of chromosome 17p; 17 displayed an unmutated immunoglobulin variable heavy chain status. The median number of cycles administered was 26. Among patients treated frontline, the best overall response rate (ORR) was 90.0%. In patients receiving ibrutinib as a second or later line ORR was 97.2%. Median progression-free survival was 28.8 and 21.1 months for patients treated frontline and as second/later line, respectively. Median overall survival was not reached for those treated frontline and resulted in 4.9 years for patients treated as second/later line. Grade 3-4 hematological toxicities were neutropenia, thrombocytopenia, and anemia. Grade 3-4 extrahematological toxicities included diarrhea, cutaneous rash, utero-vesical prolapse, vasculitis, and sepsis. Ibrutinib is effective and well tolerated in CLL. Responses obtained in a real-life setting are durable and the safety profile of the drug is favorable.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available